Literature DB >> 23140291

Apigenin Modulates Insulin-like Growth Factor Axis: Implications for Prevention and Therapy of Prostate Cancer.

Melissa A Babcook1, Sanjay Gupta.   

Abstract

Aberrant changes to the insulin-like growth factor (IGF) axis promote prostate cancer development and progression, adaptation for growth and survival in a castrate environment, and invasive metastasis. Natural and/or synthetic compounds that target the IGF axis to prevent or reverse theses abnormalities may be extremely useful in the chemoprevention and/or chemotherapy of prostate cancer. Apigenin, a naturally-occurring flavone found in many fruits and vegetables, is one such compound that can correctively modulate the IGF axis to induce growth arrest and apoptosis in many pre-clinical in vitro and in vivo models of prostate cancer. Because of its known mechanism of action, low toxicity, and effectiveness at physiologically relevant levels in animal models of prostate cancer, apigenin is an excellent candidate for a pilot study to determine the effect of apigenin supplementation on prostate cancer development and progression in humans.

Entities:  

Year:  2012        PMID: 23140291      PMCID: PMC4020998     

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  85 in total

1.  The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor.

Authors:  S M Leal; Q Liu; S S Huang; J S Huang
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Influence of biotransformation of luteolin, luteolin 7-O-glucoside, 3',4'-dihydroxyflavone and apigenin by cultured rat hepatocytes on antioxidative capacity and inhibition of EGF receptor tyrosine kinase activity.

Authors:  Doreen Schlupper; Sabine Giesa; Rolf Gebhardt
Journal:  Planta Med       Date:  2006-05-29       Impact factor: 3.352

Review 3.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis.

Authors:  B Liu; H Y Lee; S A Weinzimer; D R Powell; J L Clifford; J M Kurie; P Cohen
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

5.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.

Authors:  P Cohen; H C Graves; D M Peehl; M Kamarei; L C Giudice; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1992-10       Impact factor: 5.958

6.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

Authors:  A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

7.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.

Authors:  A Wolk; C S Mantzoros; S O Andersson; R Bergström; L B Signorello; P Lagiou; H O Adami; D Trichopoulos
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

8.  Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2009-03       Impact factor: 4.784

9.  Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.

Authors:  Chu Chen; S Kay Lewis; Lynda Voigt; Annette Fitzpatrick; Stephen R Plymate; Noel S Weiss
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

10.  Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.

Authors:  Charles J Ryan; Christopher M Haqq; Jeffrey Simko; Daisuke F Nonaka; June M Chan; Vivian Weinberg; Eric J Small; Ira D Goldfine
Journal:  Urol Oncol       Date:  2007 Mar-Apr       Impact factor: 3.498

View more
  2 in total

1.  Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.

Authors:  Jian-Ge Qiu; Lin Wang; Wen-Jing Liu; Ju-Feng Wang; Er-Jiang Zhao; Feng-Mei Zhou; Xiang-Bo Ji; Li-Hong Wang; Zhong-Kun Xia; Wei Wang; Marie Chia-Mi Lin; Ling-Zhi Liu; Ying-Xue Huang; Bing-Hua Jiang
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

Review 2.  Therapeutic Targeting of the IGF Axis.

Authors:  Eliot Osher; Valentine M Macaulay
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.